Molecular Pathology of Fibroepithelial Neoplasms of the Breast

Fig. 14.1

Schematic representation biphasic progression of fibroepithelial tumors

PT is further classified into benign, borderline and malignant categories. Due to some overlapping histologic features, differentiation of FA and benign PT and accurate grading of PT may be difficult on small biopsies. Due to significant differences in their clinical behavior, complete excision of such indeterminate lesions on needle biopsies may be needed with appropriate clinical correlation for definitive classification of fibroepithelial tumors. Some immunohistochemical markers have shown promise to aid in this differential diagnosis, especially Ki67 proliferation index. But as of now, there is no “magic marker” with high sensitivity and specificity and morphology on a completely resected tumor remains the gold standard. Large scale or multi-institutional studies with long follow-up may be needed to address these issues in the future.

References

Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, Schuyler PA. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 1994;331(1):10–5.CrossRefPubMed

Noguchi S, Yokouchi H, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Progression of fibroadenoma to phyllodes tumor demonstrated by clonal analysis. Cancer. 1995;76(10):1779–85.PubMed

Giri D. Recurrent challenges in the evaluation of fibroepithelial lesions. Arch Pathol Lab Med. 2009;133(5):713–21.PubMed

Komenaka IK, El-Tamer M, Pile-Spellman E, Hibshoosh H. Core needle biopsy as a diagnostic tool to differentiate phyllodes tumor from fibroadenoma. Arch Surg. 2003;138(9):987–90.CrossRefPubMed

Jacobs TW, Chen YY, Guinee DG Jr, Holden JA, Cha I, Bauermeister DE, Hashimoto B, Wolverton D, Hartzog G. Fibroepithelial lesions with cellular stroma on breast core needle biopsy: are there predictors of outcome on surgical excision? Am J Clin Pathol. 2005;124(3):342–54.CrossRefPubMed

Tsang AK, Chan SK, Lam CC, Lui PC, Chau HH, Tan PH, Tse GM. Phyllodes tumours of the breast—differentiating features in core needle biopsy. Histopathology. 2011;59(4):600–8.CrossRefPubMed

Jara-Lazaro AR, Akhilesh M, Thike AA, Lui PC, Tse GM, Tan PH. Predictors of phyllodes tumours on core biopsy specimens of fibroepithelial neoplasms. Histopathology. 2010;57(2):220–32.CrossRefPubMed

Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Clonal analysis of fibroadenoma and phyllodes tumor of the breast. Cancer Res. 1993;53(17):4071–4.PubMed

Noguchi S, Aihara T, Koyama H, Motomura K, Inaji H, Imaoka S. Clonal analysis of benign and malignant human breast tumors by means of polymerase chain reaction. Cancer Lett. 1995;90(1):57–63.CrossRefPubMed

10.

Kuijper A, Buerger H, Simon R, Schaefer KL, Croonen A, Boecker W, van der Wall E, van Diest PJ. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J Pathol. 2002;197(5):575–81.CrossRefPubMed

11.

Flint DJ, Tonner E, Beattie J, Allan GJ. Role of insulin-like growth factor binding proteins in mammary gland development. J Mammary Gland Biol Neoplasia. 2008;13(4):443–53.CrossRefPubMed

12.

Gross JM, Yee D. The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance. Cancer Metastasis Rev. 2003;22(4):327–36.CrossRefPubMed

13.

Allan GJ, Beattie J, Flint DJ. The role of IGFBP-5 in mammary gland development and involution. Domest Anim Endocrinol. 2004;27(3):257–66.CrossRefPubMed

14.

Mohanraj L, Oh Y. Targeting IGF-I, IGFBPs and IGF-I receptor system in cancer: the current and future in breast cancer therapy. Recent Pat Anticancer Drug Discov. 2011;6(2):166–77.CrossRefPubMed

15.

Sawyer EJ, Hanby AM, Poulsom R, Jeffery R, Gillett CE, Ellis IO, Ellis P, Tomlinson IP. Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast. J Pathol. 2003;200(5):627–32.CrossRefPubMed

16.

Sawyer EJ, Hanby AM, Ellis P, Lakhani SR, Ellis IO, Boyle S, Tomlinson IP. Molecular analysis of phyllodes tumors reveals distinct changes in the epithelial and stromal components. Am J Pathol. 2000;156(3):1093–8.PubMedCentralCrossRefPubMed

17.

Sawhney N, Garrahan N, Douglas-Jones AG, Williams ED. Epithelial–stromal interactions in tumors. A morphologic study of fibroepithelial tumors of the breast. Cancer. 1992;70(8):2115–20.PubMed

18.

Paul S, Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma. 2008;55(3):165–76.PubMed

19.

Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther. 2004;3(1):36–41.CrossRefPubMed

20.

Karim RZ, Gerega SK, Yang YH, Horvath L, Spillane A, Carmalt H, Scolyer RA, Lee CS. Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. J Clin Pathol. 2009;62(11):1016–20.CrossRefPubMed

21.

Mahipal A, Kothari N, Gupta S. Epidermal growth factor receptor inhibitors: coming of age. Cancer Control. 2014;21(1):74–9.PubMed

22.

Kersting C, Kuijper A, Schmidt H, Packeisen J, Liedtke C, Tidow N, Gustmann C, Hinrichs B, Wulfing P, Tio J, et al. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest. 2006;86(1):54–61.CrossRefPubMed

23.

Zelada-Hedman M, Werer G, Collins P, Backdahl M, Perez I, Franco S, Jimenez J, Cruz J, Torroella M, Nordenskjold M, et al. High expression of the EGFR in fibroadenomas compared to breast carcinomas. Anticancer Res. 1994;14(5A):1679–88.PubMed

24.

Nielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl. 2001;234:93–9.CrossRefPubMed

25.

Dai N, Rapley J, Angel M, Yanik MF, Blower MD, Avruch J. mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry. Genes Dev. 2011;25(11):1159–72.PubMedCentralCrossRefPubMed

26.

Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 2005;280(18):18517–24.CrossRefPubMed

Only gold members can continue reading. Log In or Register to continue